A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

NCT01614899 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

457

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SM-13496 40mg
DRUG: SM-13496 80mg
DRUG: Placebo

Sponsor

Sumitomo Pharma Co., Ltd.